The effects of fluoxetine on cognitive functions in animal model of Alzheimer's disease

Psychiatria Danubina

Volumn 16, Issue 1-2, 2004, Pages 15-20

  Ivković, Maja ^a   Damjanović, Aleksandar ^a   Jašović Gašić, Miroslava ^a   Paunović, Vladimir R ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Alzheimer's disease; Fluoxetine; Learning and memory; Rats; Sigma receptors

Indexed keywords

ACETYLCHOLINE; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SIGMA RECEPTOR LIGAND;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; EXPERIMENTAL MODEL; LEARNING; MALE; MEMORY; MEYNERT BASAL NUCLEUS; NONHUMAN; OLIVARY NUCLEUS; PREFRONTAL CORTEX; PROTEIN DEFICIENCY; PROTEIN LOCALIZATION; RAT; RAT STRAIN; RECEPTOR AFFINITY; RISK FACTOR; TISSUE DISTRIBUTION;

EID: 3042524560     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alafuzoff I, Iqbal K, Friden H, Adolfsson R and Winbald B: Histopathological criteria for progressive dementing disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol, 1987; 74: 209-225.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Forth ed. Washington DC: American Psychiatric Association, 1994.
3. Ballenger JC, Wheadon DE, Steiner M, Bushnell W and Geregel IP: Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry, 1998; 155: 36-42.
4. Blass JP and Poirer J: Pathophsysiology of the Alzheimer syndrome, 17-35. In: Gautheir S (Ed.): Clinical diagnosis and management of Alzheimer's disease. Martin Dunitz Ltd, London, 1996.
5. Bergeron R, Debonnel G, De Montigny: Potential implication of sigma ligands and of some neurosteroids in depression. Eur J Pharmacol, 1993; 240:319.
6. Doraiswamy PM, Krishnan KR, Oxman T, Jenkyn LR, Coffy DJ, Burt T, Clary CM: Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci, 2003; 58 (12): 1137-44.
7. Galasko D, Hansen LA, Katzman R, Wiedorholt W, Masliah E, Terry R et al.: Clinical-pathological correlations in Alzheimer's disease and related dementias. Arch Neurol, 1994; 51:888-895.
8. Hardy J: Molecular pathology of Alzheimer's disease. Lancet, 1991; 17:1342-1343.
9. Hepler DJ, Wenk GL, Cribbs BL, Olton DS and Coyle JT: Memory impairments following basal forebrain lesions. Brain Res, 1985; 346:8-14.
10. Kessler J, Markowitsch HJ, Sigg G: Memory related role of the posterior cholinergic system. Int J Neurosci, 1986; 30:101-119.
11. Matsuno K, Matsunaga K, Senda T, Mita S: Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. J Pharmacol. Exp Ther, 1993; 265: 851-859.
12. Maurice T, Phan VL, Urani A, Kamei A, Noda S, Nabeshima T: The beneficial effects of sigma receptor agonists in pharmacological and pathological models of amnesia. Jpn J Pharmacol, 1999; 81:125.
13. Maurice T, Hiramatsu M, Iroh J, Kameyama T, Hasegawa T, Nabeshima T: Behavioral evidence for a modulating role of sigma ligands in memory process. I. Attenuation of dizocilpine (MK 801)-induced amnesia. Brain Res, 1994; 647:44-56.
14. Meneses A and Hong E: Fluoxetine and associative learning in aged primates. Pharmacol Biochem Behav, 1995; 52:341.
15. Miyamoto M, Shintani M, Nagaoka A, Nagawa Y: Lesioning of the basal forebrain leads to memory impairments in passive and active avoidance tasks. Brain Res, 1985; 328:97-104.
16. Mrijers RB, Polsken GL, Noble S: Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging, 2002; 19 (5): 377-92.
17. Nabeshima T: Pharmacology of sigma drugs developed in Japan. Int J Neuropsychopharmacol, 1998; 1 (1): 7.
18. Narita N, Hashimoto K, Tomitaka S, Minabe Y, Yamazaki K: Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol, 1996; 307:117-119.
19. Popovic M, Jovanova-Nesic K, Popovic N, Bokonjic D, Dobric S, Rosic N et al.: Behavioral and adaptive status in an experimental model of Alzheimer's disease in rats. Int J Neurosci, 1996; 86:281-299.
20. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment. implications for the pharmacotherapy of depression. Pharmacopsychiatry, 1997; 29:23-26.
21. Smith G: Animal models of Alzheimer's disease: experimental cholinergic denervation. Brain Res Rev, 1988; 13:103-118.
22. Stahl MMS, Lindquist M, Pettersson M, Edwards I R, Sanderson J H, Taylor N F A et al.: Withdrawal reactions with selective serotonin reuptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol, 1998; 53: 163-169.
23. Struble RG, Lehmann J and Mitchell SJ: Basal forebrain neurons provide major cholinergic innervation of primate neocortex. Neurosci Lett, 1986; 66:215-220.
24. Hayashi T, Maurice T and Su TP: Sigma receptors and intracellular calcium signaling. J Pharmacol Exp Ther, 2000; 293:788.
25. Wenk H: The nucleus basalis magnocellularis Meynert (NBmM) complex - a central integrator of coded "limbic signals" linked to neocortical modular operation? A proposed (heuristic) model of function. J Hirnforschung, 1989; 30:127-151.